While continuation funds are increasingly common liquidity solutions, not all of them are delivering the appropriate returns, according to Cari Lodge, head of secondaries at Commonfund.
The fund will be managed by Ant Solutions Partners, a newly formed spinoff of Ant Capital’s Solution Investment Group.
The firm was a participating investor in a single-asset CV for Essential Pharma.
In this podcast, CVC's Carlo Pirzio-Biroli and Kirkland's Ted Cardos literally peel back the onion on the year that was and look forward to what they believe will shape the secondaries market in 2025.
The firm’s third private credit secondaries fund in the series could be its largest to date.
Swiss GP Gyrus Capital originally invested in Essential Pharma in 2019 as part of a family/founder succession plan process.
The UK pension fund is about to close its second private debt fund, which it aims to scale to £500m, and is looking to consolidate GP partnerships.
Coller Capital's latest barometer has found that most investors see the main purpose of continuation funds as providing an alternative to selling assets at a low valuation.
The firm defines RE deals as any transaction where private equity is exchanged in the capital stack and where the operator maintains control over the asset.
The programme involves both GP-leds and LP-leds, Mathieu Forcioli, global and APAC head of alternatives for HSBC Global Private Banking, tells Secondaries Investor.